ContraFect Stock Price, News & Analysis (NASDAQ:CFRX) $0.05 -0.02 (-27.95%) (As of 02:44 PM ET) Add Compare Share Share Today's Range$0.05▼$0.0650-Day Range$0.05▼$0.5852-Week Range$0.04▼$13.02Volume504,419 shsAverage Volume1.39 million shsMarket Capitalization$535,000.00P/E RatioN/ADividend YieldN/APrice Target$3.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media ContraFect MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside6,464.6% Upside$3.00 Price TargetShort InterestHealthy1.09% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.44) to ($1.50) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.98 out of 5 stars 3.5 Analyst's Opinion Consensus RatingContraFect has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.00, ContraFect has a forecasted upside of 6,464.6% from its current price of $0.05.Amount of Analyst CoverageContraFect has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.09% of the float of ContraFect has been sold short.Short Interest Ratio / Days to CoverContraFect has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ContraFect has recently decreased by 48.62%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldContraFect does not currently pay a dividend.Dividend GrowthContraFect does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CFRX. Previous Next 1.1 News and Social Media Coverage Search Interest3 people have searched for CFRX on MarketBeat in the last 30 days. MarketBeat Follows3 people have added ContraFect to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ContraFect insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.62% of the stock of ContraFect is held by insiders.Percentage Held by InstitutionsOnly 7.85% of the stock of ContraFect is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ContraFect are expected to grow in the coming year, from ($3.44) to ($1.50) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ContraFect is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ContraFect is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About ContraFect Stock (NASDAQ:CFRX)ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus. The company also developing CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also developing CF-296, an osteomyelitis and PJI which is in preclinical trailers for the treatment of joint infections. In addition, the company developing Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. Further, It develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York.Read More CFRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CFRX Stock News HeadlinesNovember 28, 2023 | americanbankingnews.comContraFect (NASDAQ:CFRX) Stock Price Crosses Below 50-Day Moving Average of $0.33November 28, 2023 | americanbankingnews.comContraFect (NASDAQ:CFRX) Earns Sell Rating from Analysts at StockNews.comDecember 5, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 19, 2023 | morningstar.comContraFect Corp CFRXNovember 14, 2023 | washingtonpost.comContraFect: Q3 Earnings SnapshotOctober 23, 2023 | benzinga.comWhy Troika Media Group Shares Are Trading Lower By Over 20%; Here Are 20 Stocks Moving PremarketOctober 16, 2023 | msn.comWhy Is ContraFect (CFRX) Stock Up 23% Today?October 16, 2023 | finance.yahoo.comContraFect Announces FDA Clearance of CF-370 IND Application to Proceed With Phase 1 Clinical StudyDecember 5, 2023 | Financial Alphas (Ad)Countries Are Investing Heavily Into Securing Energy IndependenceThere's a worldwide "arms race" for countries to secure lithium - the critical metal essential to powering the world's green energy transition. While the U.S. is now investing heavily into lithium production, the North American supply chain has fallen far behind. One company is on a mission to change that and make a previously remote area the next great lithium mining hub.October 10, 2023 | benzinga.comWhy Immunic Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving PremarketSeptember 21, 2023 | finance.yahoo.comCFRX: IND Application for CF-370 Submitted to FDA…September 19, 2023 | markets.businessinsider.comAnalysts’ Top Healthcare Picks: ContraFect (CFRX), Boston Scientific (BSX)September 19, 2023 | finance.yahoo.comContraFect to Present at the ASM/ESCMID Joint Conference on Drug DevelopmentSeptember 18, 2023 | finance.yahoo.comContraFect Announces Submission of IND Application to the FDA for its Development Candidate CF-370August 28, 2023 | finance.yahoo.comContraFect to Present at the World Anti-Microbial Resistance Congress 2023August 17, 2023 | finance.yahoo.comCFRX: CF-370 IND to be Filed in 3Q23…August 15, 2023 | markets.businessinsider.comContraFect (CFRX) Receives a Buy from Maxim GroupAugust 14, 2023 | sfgate.comContraFect: Q2 Earnings SnapshotAugust 14, 2023 | finance.yahoo.comContraFect Reports Second Quarter 2023 Financial Results and Provides Business UpdateJuly 25, 2023 | money.usnews.comContraFect CorpJuly 6, 2023 | msn.comContraFect (CFRX) Price Target Decreased by 97.37% to 5.10June 27, 2023 | msn.comContraFect enters a warrant exercise transaction for $9.6MJune 27, 2023 | finance.yahoo.comContraFect Enters Into a Warrant Exercise Transaction for Proceeds of $9.6 MillionJune 22, 2023 | marketwatch.com8-K: CONTRAFECT CorpJune 22, 2023 | finance.yahoo.comCFRX: CF-370 Effective in Rabbit Lung Infection Model Caused by Klebsiella Pneumoniae…June 20, 2023 | finance.yahoo.comContraFect Data Presentations at ASM Microbe 2023 Demonstrate the Power of the Company’s Proprietary Platform to Discover New Agents Targeting Antibiotic-Resistant Gram-negative PathogensJune 9, 2023 | msn.comContraFect Gains with Key Data Presentation Set for Next WeekSee More Headlines Receive CFRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ContraFect and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/14/2023Today12/05/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CFRX CUSIPN/A CIK1478069 Webwww.contrafect.com Phone(914) 207-2300FaxN/AEmployees23Year FoundedN/APrice Target and Rating Average Stock Price Target$3.00 High Stock Price Target$3.00 Low Stock Price Target$3.00 Potential Upside/Downside+4,794.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($19.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-65,150,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-138.70% Debt Debt-to-Equity RatioN/A Current Ratio0.53 Quick Ratio0.53 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($19.92) per share Price / Book0.00Miscellaneous Outstanding Shares10,700,000Free Float10,639,000Market Cap$655,910.00 OptionableNot Optionable Beta0.29 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Roger James Pomerantz FACP (Age 66)M.D., Chairman, CEO & President Comp: $970.72kMr. Michael Messinger CPA (Age 48)Chief Financial Officer Comp: $543.14kMs. Natalie Bogdanos J.D. (Age 54)General Counsel, Corporate Secretary & Data Protection Officer Comp: $531.2kMr. Matthew Salamone P.H.R.SPHR, Vice President of Human ResourcesDr. Gary Woodnutt (Age 66)Senior Vice President of Translational Sciences & Preclinical Development Dr. William Garrett Nichols M.D. (Age 54)M.S., Interim Chief Medical Officer More ExecutivesKey CompetitorsGalmed PharmaceuticalsNASDAQ:GLMDTharimmuneNASDAQ:THAROncorusNASDAQ:ONCRBaudax BioNASDAQ:BXRXBellerophon TherapeuticsNASDAQ:BLPHView All CompetitorsInstitutional OwnershipArmistice Capital LLCBought 419,258 shares on 11/15/2023Ownership: 4.439%View All Institutional Transactions CFRX Stock Analysis - Frequently Asked Questions Should I buy or sell ContraFect stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ContraFect in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" CFRX shares. View CFRX analyst ratings or view top-rated stocks. What is ContraFect's stock price target for 2024? 1 analysts have issued 1-year target prices for ContraFect's shares. Their CFRX share price targets range from $3.00 to $3.00. On average, they expect the company's share price to reach $3.00 in the next twelve months. This suggests a possible upside of 6,464.6% from the stock's current price. View analysts price targets for CFRX or view top-rated stocks among Wall Street analysts. How have CFRX shares performed in 2023? ContraFect's stock was trading at $7.68 on January 1st, 2023. Since then, CFRX shares have decreased by 99.4% and is now trading at $0.0457. View the best growth stocks for 2023 here. Are investors shorting ContraFect? ContraFect saw a decrease in short interest during the month of October. As of October 31st, there was short interest totaling 59,600 shares, a decrease of 48.6% from the October 15th total of 116,000 shares. Based on an average daily volume of 217,000 shares, the days-to-cover ratio is presently 0.3 days. Approximately 1.1% of the company's stock are sold short. View ContraFect's Short Interest. How were ContraFect's earnings last quarter? ContraFect Co. (NASDAQ:CFRX) announced its quarterly earnings data on Tuesday, November, 14th. The biotechnology company reported ($0.50) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.66) by $0.16. When did ContraFect's stock split? ContraFect shares reverse split on Tuesday, February 14th 2023. The 1-80 reverse split was announced on Tuesday, February 14th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 14th 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. What other stocks do shareholders of ContraFect own? Based on aggregate information from My MarketBeat watchlists, some companies that other ContraFect investors own include SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), Verastem (VSTM), Vaxart (VXRT), Matinas BioPharma (MTNB), VBI Vaccines (VBIV), Novavax (NVAX), Cidara Therapeutics (CDTX), Gilead Sciences (GILD) and Dynavax Technologies (DVAX). Who are ContraFect's major shareholders? ContraFect's stock is owned by many different institutional and retail investors. Top institutional investors include Armistice Capital LLC (4.44%) and Concourse Financial Group Securities Inc. (0.00%). View institutional ownership trends. How do I buy shares of ContraFect? Shares of CFRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:CFRX) was last updated on 12/5/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ContraFect Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.